Unite union 'will fight' Biomet's plans to close its Bridgend facility
It's after nearly 550 jobs are feared could be lost
The Unite Union says it's going to fight the Biomet UK proposal to close its facility in Bridgend.
It's after nearly 550 jobs are feared could be lost.
There'll now be a six month consultation period, which Unite say they'll work hard to see a viable future for the site.
The union says it's reacted 'with shock' at the announcement that 544 jobs could be lost.
Peter Hughes, Unite Wales Regional Secretary said; “The news today that Biomet are proposing a site closure of their facility at Bridgend will be devastating news to our members and their communities.
"Unite will explore every avenue available to prevent the current proposal from proceeding. Almost 550 well-paid, highly skilled jobs are at stake here, and the Bridgend area cannot absorb the economic impact this closure would bring.
During the six month consultation period Unite will fight for jobs and a viable future for the site."
In a statement, Maria Silva, Plant Director, Zimmer Biomet Bridgend, said: "Zimmer Biomet announced a proposal to cease manufacturing in Bridgend, Wales.
"The local leadership team has met with union representatives and employees to advise them of the proposal and will begin a consultation to evaluate alternatives and how to limit the loss of jobs.  
"Zimmer Biomet employs 540 team members at the manufacturing site.
"We recognise the effect a closure would have on team members and the community, and we are committed to treating people with dignity and respect, and to being as transparent as possible throughout the consultation.
"Our focus is on maintaining a robust supply chain and reliable delivery to our customers. If a decision is taken to proceed, we have planned how to transfer production safely and effectively to other locations in Zimmer Biomet’s global network.
"This announcement does not affect team members in our UK Commercial and R&D teams or at the Bridgend commercial distribution centre.
"We remain committed to customers, patients and team members in the UK, as we continue to invest in R&D and bring innovative solutions to market."